It is made available under a CC-BY-NC 4.0 International license .

A multi-level gene-diet interaction analysis of fish oil supplementation and 14 circulating polyunsaturated fatty acids-related traits identifies the FADS and GRP12 loci

Susan Adanna Ihejirika¹, Alexandra Huong Chiang², Aryaman Singh², Eunice Stephen², Han Chen³, Kaixiong Ye^{1,2*}

¹Institute of Bioinformatics, University of Georgia, Athens, GA, 30602, USA

² Department of Genetics, University of Georgia, Athens, GA, 30602, USA

³ Human Genetics Center, Department of Epidemiology, School of Public Health, The

University of Texas Health Science Center at Houston, Houston, TX, 77030, USA

*Corresponding Author:

Kaixiong Ye, PhD Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East Green Street, Athens, GA 30602 Phone: 706-542-5898 Email: kaixiong.ye@uga.edu

It is made available under a CC-BY-NC 4.0 International license .

1 Abstract

2 Fish oil supplements (FOS) are known to alter circulating levels of polyunsaturated fatty 3 acids (PUFAs) among individuals but in a heterogeneous manner. These varied 4 responses may result from unidentified gene-FOS interactions. To identify genetic 5 factors that interact with FOS to alter the circulating levels of PUFAs, we performed a 6 multi-level genome-wide interaction study (GWIS) of FOS on 14 plasma measurements 7 in 200,060 unrelated European-ancestry individuals from the UK Biobank. From our 8 single-variant tests, we identified genome-wide significant interacting SNPs ($P < 5 \times 10^{-5}$ 9 ⁸) in the FADS1-FADS2 gene cluster for total omega-3, omega-3%, docosapentaenoic 10 acid (DHA), DHA% and the omega-6 to omega-3 ratio. Among the interaction signals for 11 omega-3%, the lead SNP, rs35473591 (C>CT, CT allele frequency = 0.34), had a lower 12 association effect size in the FOS-taking group ($\beta = 0.35$ for allele C) than that in the 13 group without FOS (β = 0.42). Likewise, the effect sizes of associations between FOS 14 and omega-3% varied across the three genotype groups ($\beta = 0.45, 0.50, \text{ and } 0.59, \dots$ respectively, in C/C, C/CT, and CT/CT). Our gene-level aggregate and transcriptome-15 16 wide interaction analyses identified significant signals at two loci, around FADS1-17 FADS2 and GRP12. The contribution of genome-wide gene-FOS interactions to 18 phenotypic variance was statistically significant in omega-3-related traits. This systemic 19 gene-FOS GWIS contributes to our understanding of the genetic architecture of 20 circulating PUFAs underlying FOS response and informs personalized dietary 21 recommendations.

22

It is made available under a CC-BY-NC 4.0 International license .

23 Introduction

Genetic¹⁻³ and environmental factors, such as diet⁴⁻⁶, influence the circulating levels of 24 polyunsaturated fatty acids (PUFAs). PUFAs are fatty acids with 18 to 24 carbons and 25 multiple double bonds. They fall into two main families, omega-3 and omega-6, 26 27 depending on which carbon the first double bond falls on from the methyl end of the carbon chain. PUFAs play crucial roles in various physiological processes, including 28 29 immune function, cardiovascular health, brain development, and cognitive performance.⁷⁻⁹ Alpha-linolenic acid (ALA) and linoleic acid (LA) are essential omega-3 30 31 and omega-6 fatty acids, respectively, that can only be obtained from dietary sources and act as precursors for synthesizing long-chain PUFAs.⁷ Long-chain PUFAs can be 32 33 obtained from diet or produced endogenously in the presence of the necessary precursors.⁷ Fish oil supplements (FOS) are a rich, readily available source of long-34 35 chain omega-3 PUFAs, particularly eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA).¹⁰ Additionally, FOS intake alters circulating PUFA concentrations similarly 36 to fish consumption.¹¹ 37

38

The interactions between genetic variants and dietary PUFAs also influence circulating PUFA concentrations.^{7,8,12-19} This means that omega-3 PUFAs obtained through FOS can alter the genetic effects on circulating PUFA levels, and that genetic variants can modify the effects of FOS on the same phenotypes. One of the relevant genetic loci, the *FADS* locus, contains the *FADS1* and *FADS2* genes, which encode the delta-5 (D5) and delta-6 (D6) desaturase enzymes, respectively. These membrane-bound enzymes introduce cis double bonds at the D5 and D6 positions in PUFAs, the rate-limiting steps

It is made available under a CC-BY-NC 4.0 International license .

in long-chain PUFA biosynthesis.^{20,21} Juan *et al.* found that higher dietary EPA and DHA 46 consumption increases circulating EPA proportions.¹² However, genotypes at the 47 48 rs174546 FADS1 SNP (C>T) impacted the extent of that increase. For every 1-standard 49 deviation (SD) increase in EPA intake, individuals with the C/C genotype saw an 50 average increase of 3.7% in the circulating EPA level, while those with the T/T genotype 51 saw an average increase of 7.8%. These gene-diet interactions may explain some of 52 the heterogeneity in circulating PUFA levels in response to omega-3 PUFA supplementation.²² Furthermore, these genotype-dependent responses may provide 53 54 some insights into the inconsistent results in observational studies and randomized 55 controlled trials (RCTs) investigating the effect of omega-3 PUFA supplementation on various outcomes,⁸ such as the risk of cardiometabolic diseases, Alzheimer's disease, 56 cancer, and inflammation.²³⁻²⁷ 57

58

59 Despite advances in characterizing genetic loci interacting with dietary omega-3 PUFAs, 60 most existing gene-dietary PUFAs interaction studies have various weaknesses and limitations. Most of them examined only candidate genes or variants¹²⁻¹⁸. Some were 61 performed in specific contexts, such as disease risk and related outcomes^{19,23-27}, while 62 others only examined circulating metabolites other than PUFAs as outcomes.^{19,28} They 63 64 were also limited by small sample sizes. This leaves a gap in understanding the effects 65 of interactions between genome-wide loci and dietary omega-3 PUFAs on circulating 66 PUFAs in a generally healthy cohort.

It is made available under a CC-BY-NC 4.0 International license .

- To this end, we conducted a large-scale gene-diet interaction analysis (N=200,060) of
- 69 FOS on 14 circulating PUFAs-related measurements in the UK Biobank cohort^{29,30} to
- 70 systematically identify genetic factors that interact with FOS to alter levels of plasma
- 71 PUFAs. We then performed a transcriptome-wide interaction study (TWIS) to identify
- 72 genes whose expression interacts with FOS. Lastly, we estimated the phenotypic
- variance explained by genome-wide interactions with FOS. Our study is the first large-
- scale GWIS of FOS on the circulating levels of PUFAs.

It is made available under a CC-BY-NC 4.0 International license .

75 Methods

76 Cohort

- The UK Biobank is a large, population-based prospective study of over 500,000
- volunteer participants recruited between 2006 and 2010 from across England, Wales,
- and Scotland. The participants were between the ages of 40 and 69 years. At
- 80 recruitment, participants provided sociodemographic, lifestyle, environmental, clinical,
- 81 and biochemical information through touchscreen questionnaires, face-to-face
- 82 interviews, and physiological measurements. Plasma samples were provided for
- 83 genotyping and nuclear magnetic resonance (NMR) spectroscopy-based metabolomic
- 84 measurements.^{29,30} The UK Biobank received ethical approval from the National
- 85 Research Ethics Service Committee North West–Haydock (reference ID 11/ NW/0382).
- 86 The use of participants' data in this study was approved under Project 48818.
- 87

88 Participant Inclusion and Exclusion

89 In this study, we restricted our participants to those who were of genetically determined European ancestry³¹, did not have a high degree of kinship with other volunteers, were 90 91 not outliers for heterozygosity or missing genotype rate, had matched self-reported and 92 genetic sex, and had no sex chromosome aneuploidy (Figure S1). All UK Biobank 93 participants provided written informed consent upon recruitment, authorizing the storage 94 and use of their provided biological, medical, and genetic data for health-related 95 research purposes. Additionally, participants who had withdrawn their consent as of February 22nd, 2022, were removed (N=114). 96

It is made available under a CC-BY-NC 4.0 International license .

98 Genotype

99	The genotype data used in this study was version 3 of the UK Biobank genotyping
100	release, previously described in detail. ²⁹ This data included genotyping of \sim 820,000
101	variants done with either the UK BiLEVE Axiom Array or the UKB Axiom Array. It also
102	included initial quality control and imputation of variants using a merged reference panel
103	of the Haplotype Reference Consortium (HRC) and UK10K. ²⁹ For further genotype QC,
104	we selected only autosomal variants with imputation quality score (INFO) > 0.5 , minor
105	allele frequency (MAF) > 1%, genotype missingness per individual < 5%, genotype
106	missingness per variant < 2%, and Hardy-Weinberg equilibrium (HWE) p -value < 1.0 x
107	10 ⁻⁶ using PLINK2 alpha-v2.3. ³²
108	
109	Phenotype
110	Finland-based Nightingale Health Ltd. performed NMR metabolomic measurement of
111	251 metabolic biomarkers for approximately 280,000 participants. The UK Biobank
112	released this data in two phases – Phases One and Two. Phase One release consisted
113	of plasma measurements for 120,000 randomly selected samples. Phase Two
114	consisted of measurements for individuals in Phase One and an additional 170,000
115	samples. Absolute circulating levels of fatty acids, including PUFAs and
116	monounsaturated fatty acids (MUFAs), were measured and reported in mmol/L. The
117	proportion of each PUFA to total fatty acids was expressed as a percentage. We
118	investigated 14 circulating PUFAs and MUFAs-related traits as our outcomes. The 14
119	phenotypes were the absolute circulating levels of total PUFAs, total MUFAs, omega-3
120	PUFAs, omega-6 PUFAs, LA, and DHA; their relative percentages in total fatty acids

It is made available under a CC-BY-NC 4.0 International license .

121 (i.e., PUFAs%, MUFAs%, omega-3%, omega-6%, LA%, and DHA%), and the ratios of

122 PUFAs to MUFAs and omega-6 to omega-3. All phenotypes were rank-based inverse

123 normal transformed.

124

125 **Dietary Exposure**

The primary exposure of interest in this study is FOS. We used the UK Biobank dietary questionnaire administered during recruitment to determine the exposure status. This questionnaire was a touchscreen survey about the intake frequency of common food and drink items. A total of 497,666 participants filled these out during the initial assessment center visit between 2006 and 2010. Participants were asked about mineral and other dietary supplements, "Do you regularly take any of the following? (You can select more than one answer)", and "fish oil (including cod liver oil)" was one of the

133 options (Data Field 6179).

134

135 Genome-wide Interaction Analysis

We performed single-variant interaction tests with the Gene-Environment interaction analysis in Millions of samples (GEM) tool.³³ GEM implements a generalized linear model for unrelated individuals. GEM conducts tests for marginal effects, interaction effects (1-degree of freedom tests), and joint tests for genetic main and interaction effects (2-degree of freedom tests). In this analysis, only results from the 1-degree of freedom (1df) test were interpreted due to our interest in strong interaction effects. We used age, sex, age-by-sex, and the first ten principal components as the covariates in

It is made available under a CC-BY-NC 4.0 International license .

our model. Genome-wide significance *p*-value of 5.0×10^{-8} was used to define

- 144 significant interactions.
- 145
- 146 To interpret the interaction signals identified by GEM, we used PLINK2 alpha-v2.3 to
- 147 conduct exposure-stratified analysis to quantify SNP effects in each exposure group.
- Lastly, to quantify the effects of FOS across the genotype groups, we fitted linear
- 149 models to each group and adjusted for the same covariates as in our single-variant
- 150 interaction tests.
- 151

152 Gene-level Interaction Analysis

- 153 FUMA³⁴ was used to implement the MAGMA model³⁵, which maps variants to genes 154 based on physical locations, aggregates *p*-values from the individual variant-FOS
- 155 interaction tests across genic regions, and tests gene-level associations with each of
- 156 the phenotypes of interest. Variants were mapped to 18,767 genes based on defined
- 157 transcription start and stop sites, and a *p*-value of 2.66×10^{-6} (0.05/18767) was used to
- 158 define statistical significance. Linkage disequilibrium (LD) was estimated using the UK
- 159 Biobank release 2b 10k white British reference panel.
- 160

161 Transcriptome-wide Interaction Analysis

- 162 We used the MetaXcan framework for our TWIS to integrate eQTL information with
- 163 single-variant GWIS summary statistics. MetaXcan tools include S-PrediXcan³⁶ and S-
- 164 MultiXcan.³⁷ S-PrediXcan predicts and imputes genetically determined gene expression
- 165 levels and tests their associations with the phenotype of interest. We used the MASHR-

It is made available under a CC-BY-NC 4.0 International license .

166 based models to predict gene expression. These models are based on fine-mapped 167 variants for each tissue. They take in gene expression weights, the variance and 168 covariances of SNPs, and the beta coefficient of each SNP from summary statistics. S-169 MultiXcan aggregates information across all tissues. After multiple testing correction for 170 the number of genes that had a prediction model in at least one tissue, significance was defined as $p < 2.9 \times 10^{-6}$ (0.05/17,500). 171 172 173 Estimation of Phenotypic Variance Explained by Gene-FOS Interactions We performed GCTA-GREML³⁸ analysis to estimate the proportion of phenotypic 174 175 variance explained by genome-wide gene-FOS interactions for each of the 14 176 phenotypes separately. We estimated the genetic relationship matrix (GRM) between 177 pairs of individuals using LD-pruned SNPs. SNPs were pruned using a window size of 1000 variants, a step size of 100 variants, and an r^2 of 0.9. 178 179 180 To estimate the variance explained by the top variant, we assumed gene-environment

- 181 independence and applied the formula
- 182 $2\beta_{G \times E}^2 f(1-f)p(1-p)$

183 where β is the gene-FOS interaction effect size, *f* is the MAF, and *p* is the exposure

184 prevalence in the population.

It is made available under a CC-BY-NC 4.0 International license .

185 **Results**

186 **Sample characteristics**

- 187 NMR metabolite measurements for UK Biobank participants were released in two
- phases Phase One (N = 120,000) and Phase Two (N = 170,000 additional samples).
- 189 Phase Two release also included updated and corrected Phase One measurements
- 190 (Methods). We refer to the additional 170,000 samples as Phase Two in this study. We
- 191 performed exposure quality control on the combined dataset of 290,000 participants for
- 192 our gene-FOS interaction analysis (Figure S1). Approximately 31.8% (*N* = 63,711) of
- 193 200,060 included participants indicated regular FOS use at recruitment (Table S1). The
- 194 percentage of females and mean age in our dataset were 53.5% and 56.8 ± 8.0 ,

195 respectively.

196

197 Variant-level analysis identified interacting SNPs in the FADS locus

198 We performed single-variant 1-df interaction tests to examine the interactions between 199 FOS and genetic variants in the Phase One and Phase Two datasets, separately. We identified one and two unique loci at $p < 5.0 \times 10^{-8}$ in the Phase One and Two datasets, 200 201 respectively (Tables S2 and S3, Figures S2, S3, and S4). The correlations between the 202 *p*-values from both analyses are shown in Figure S3, with reproducible association 203 signals observed for total omega-3, omega-3%, the omega-6/omega-3 ratio, DHA, and 204 DHA%. These reproducible signals, genome-wide significant in Phase Two and 205 nominally significant in Phase One, locate in the FADS1-FADS2 gene cluster, hereafter 206 referred to as the FADS locus.

207

It is made available under a CC-BY-NC 4.0 International license .

208	Next, we performed interaction tests in the combined dataset of Phase One and Two
209	(Figure S5, Table S4). We identified genome-wide significant interaction effects for
210	variants in the FADS locus, for five traits, including total omega-3, omega-3%, DHA,
211	DHA%, and the omega-6/omega-3 ratio (Figures 1A and S5, Table 1). To report our
212	significant results, we focused on omega-3% as we observed similar trends in the other
213	four traits. Omega-3% encompasses all omega-3 PUFAs and reflects omega-3
214	concentration in relation to total fatty acids. The most significant interaction was at the
215	lead SNP rs35473591 (chr11:61586328; C>CT, MAF = 0.34) (Figure 1B). To quantify
216	the genetic effect of rs35473591 in each exposure subgroup, we performed a stratified
217	analysis (Figure 1C). The C allele had an overall positive effect on omega-3%, but its
218	effect size was lower in the FOS-taking group (β_{g} = 0.35) than in the group that does
219	not use FOS (β_{g} = 0.42). Furthermore, we fitted linear models to quantify the effect of
220	FOS in each genotype subgroup. FOS significantly altered omega-3% levels. The
221	degree of alteration varied across the three genotype groups (Figure 1D, $\beta_E = 0.45$,
222	0.50, 0.59 SD units, respectively, in C/C, C/CT, and CT/CT). Together, these results
223	highlight a significant effect of interaction between rs35473591 and FOS on omega-3%,
224	demonstrating that the effect of FOS on circulating omega-3% is modulated by
225	rs35473591 genotype. Similar interaction effects were observed at the FADS locus for
226	total omega-3, DHA, DHA%, and the omega-6/omega-3 ratio.

227

Gene-level interactions with FOS

To extend our single-variant tests, we first used MAGMA to aggregate interaction *p*values across genic regions and performed gene-based interaction tests. The *FADS*

It is made available under a CC-BY-NC 4.0 International license .

231 cluster interaction was significant in the same five traits as in the single-variant tests 232 (Figure 2). Around this FADS locus, in addition to the FADS1 and FADS2 genes, the 233 FADS3, TMEM258, MYRF, FEN1, and RAB3IL1 genes were also significant across the 234 same five traits (Figure 2A), but these signals may be driven by the same variants due 235 to the high level of LD in this genomic region. Additionally, a novel locus around the 236 GPR12 gene was significant in total PUFAs% and the ratio of PUFAs to MUFAs (Figure 237 2B). The top SNP in PUFAs%, rs1752653 (chr 13:27322777; T>C, MAF = 0.21), reached suggestive genome-wide significance at $p < 5.0 \times 10^{-6}$ (Figure 3A). *GPR12*-238 239 rs1752653 had opposite directions of genetic effects on PUFAs% in the FOS and non-FOS-taking groups, with $\beta_c = 0.03$ and -0.01, respectively (Figure 3B). Across the three 240 genotype groups, the effect of FOS on PUFAs% is β_{E} = 0.24, 0.21, and 0.16 SD units, 241 242 respectively, in T/T, T/C, and C/C (Figure 3C).

243

244 Next, we integrated eQTL information with our GWIS summary statistics using S-245 PrediXcan and S-MultiXcan. We first performed S-PrediXcan analyses to identify genes 246 whose genetically predicted expression levels interact significantly with FOS intake 247 status in each phenotype. S-PrediXcan conducted single-tissue analysis in 49 tissues 248 available in the GTEx consortium. We used S-MultiXcan to aggregate results across 249 multiple tissues and to increase power relative to the individual tissue analyses. After 250 multiple testing correction for the number of genes that had a prediction model in at least one tissue (0.05/17,500; $p < 2.9 \times 10^{-6}$), we identified 24 significant interactions 251 252 involving seven genes across five unique traits (Table S5). The FADS1, FADS2. 253 FADS3, TMEM258, FEN1, BEST1, and FTH1 genes were all significant across the

It is made available under a CC-BY-NC 4.0 International license .

254	same five traits as MAGMA gene-based analysis and our single-variant tests. The most
255	significant interaction was for the <i>FADS1</i> gene ($p = 8.8 \times 10^{-22}$) in omega-3%. The
256	FADS1 gene was also the only gene with interaction effects in all five phenotypes with
257	significant interactions. In summary, two types of gene-based analyses consistently
258	identified genes around the FADS locus to exhibit significant gene-FOS interaction
259	signals for five PUFA traits. Gene-level analysis with MAGMA further identified the
260	GPR12 locus for total PUFAs% and the ratio of PUFAs to MUFAs.
261	
262	Contribution of gene-FOS interactions to the phenotypic variance of circulating
263	PUFA levels
264	We conducted GCTA-GREML analysis to estimate the amount of phenotypic variance
265	explained by genome-wide gene-FOS interactions. The total additive genetic influence
266	(i.e., SNP heritability) across all 14 PUFA and MUFA traits ranged from 14.2% to 23.9%
267	(s.e. 0.36% and 0.37%) in LA and MUFAs%, respectively (Figure 4, Table S6). The
268	phenotypic variance explained by genome-wide gene-FOS interactions ranged from
269	0.53% to 1.51% (s.e. 0.38% and 0.39%) in omega-6% to DHA%, respectively. These
270	estimates were statistically significant in 10 out of 14 PUFA traits. The four traits without
271	significant variance explained are total PUFAs, total MUFAs, MUFAs%, and omega-6%.
272	We then estimated the contribution of the top SNP, rs35473591, to the variance
273	explained by gene-FOS interactions in omega-3%. SNP rs35473591 explained a
274	proportion of 5.12 x 10^{-4} , estimated to be 4.11% of the genome-wide gene-FOS
275	interaction contributions to omega-3% variance. Gene-FOS interactions make small but
276	non-negligible contributions to the phenotypic variance of plasma PUFA traits.

It is made available under a CC-BY-NC 4.0 International license .

277

278 **Discussion**

279 In this study, we reported the most extensive GWIS of gene-FOS interactions in 14 280 PUFAs and MUFAs-related traits. Our goal for this project was to leverage a large 281 cohort of over 200,000 European individuals in the UK Biobank to identify genetic loci 282 that modify the associations between FOS and circulating PUFA traits. We also 283 estimated the contribution of genome-wide interactions with FOS to the phenotypic 284 variance. Across 14 traits, we identified significant gene-FOS interactions for seven 285 traits – five variant and gene-level interactions in omega-3 related traits and the omega-286 6/omega-3 ratio, and two additional gene-level interactions for PUFAs% and PUFAs/MUFAs ratio. 287

288

289 In both our single-variant and gene-level analyses, we replicated the FADS1-FADS2 gene cluster identified in previous gene-dietary PUFAs interaction studies.^{12,39-41} These 290 291 studies investigated other FADS SNPs in high LD with our top SNP, rs35473591. These 292 variants do not all have the same effect on PUFAs, so it is essential to investigate each SNP's effect independently in the different PUFAs.⁷ From our results, the lead FADS1-293 294 rs35473591 SNP had different effect sizes on omega-3% in the exposure groups. The 295 genetic influence of this SNP was much more substantial in the individuals who do not 296 take fish oil. This shows that FOS lessened the FADS1-rs35473591 effect on omega-297 3%, evidence of interaction. We also saw an overall increase in omega-3-related traits and a reduction in the omega-6 to omega-3 ratio after supplementation, indicating that 298 FOS increases circulating omega-3 levels, as previously established.^{4-6,42} The ratio of 299

It is made available under a CC-BY-NC 4.0 International license .

dietary omega-6 to omega-3 consumed has drastically shifted from ~5:1 to 10:1
 because of our modern Western diets, and this is reflected in the ratio of plasma
 omega-6 to omega-3.⁴³ It is crucial to regulate this ratio because this shift has been
 associated with various chronic diseases.⁸

304

305 Our results showed that FOS intake had the lowest effect on omega-3% levels in the 306 C/C homozygote genotype group and had the highest effect in the CT/CT group. The 307 degree of omega-3% alteration increased with each copy of the CT allele. This implies 308 that individuals with the CT/CT and C/CT genotypes will benefit more from taking FOS 309 in terms of increasing omega-3 PUFA levels and reducing their omega-6/omega-3 ratio. 310 Individuals who are homozygous of the C major allele at FADS1-rs35473591 benefit 311 less, suggesting they need higher doses of FOS to attain the same circulating omega-3 312 levels as CT carriers. In summary, the FADS1-rs35473591 SNP, in the presence of 313 FOS, has an increasing effect on omega-3-related traits, but the degree of this effect is 314 genotype-dependent. We did not find any significant interaction for FADS variants in 315 omega-6-related traits. Previous studies have implicated the FADS locus in interactions with PUFA supplementation.¹³ A reasonable explanation is that our study focused on 316 omega-3 PUFA supplementation (i.e., FOS), while Sergeant et al.¹³ focused on 317 318 supplementation of gamma-linolenic acid supplementation, which is an omega-6, 18-319 carbon PUFA.

320

321 Taking only genetic main or marginal effects into account does not give a complete

322 picture of genetic impacts on circulating PUFAs. Accounting for relevant gene-

It is made available under a CC-BY-NC 4.0 International license .

323 environment interactions revealed patterns that would not be observed in a typical 324 genome-wide association study. Furthermore, revealing gene-environment interactions 325 is needed to estimate how much phenotypic variance is explained by such interactions. 326 This estimation gives a better understanding of complex traits and diseases because 327 they are influenced by a combination of genetic makeup and environmental exposures, 328 and the effects of some genes are environment-dependent. It also helps to explain 329 some of the 'missing heritability' in traits. From our results, additive genetic factors alone 330 explain a maximum of 22.5% of the phenotypic variance of omega-3-related plasma 331 levels, while gene-FOS interactions explain a maximum of 1.51%. The contributions of 332 gene-FOS interactions to omega-3 trait variance are small but non-negligible. 333 334 Our gene-based analysis revealed the G protein-coupled receptor 12 (GPR12) gene as 335 an interacting locus for PUFAs% and the PUFAs to MUFAs ratio. This gene is highly 336 expressed in the central nervous system and encodes the constitutively active G protein-coupled receptor 12 that promotes cyclic AMP production.⁴⁴ GPR12 is an 337 orphan receptor, meaning it is unconfirmed what endogenous ligand it binds to.⁴⁴ 338 339 Regarding PUFAs, it is unclear how the GPR12 receptor is associated with them. 340 However, the GPR12 receptor is phylogenetically related to cannabinoid receptors, 341 which bind to certain endocannabinoids, including omega-6-derived endocannabinoids.^{45,46} Recent evidence shows that omega-3-derived 342 endocannabinoids also exist.^{45,46} Future research to experimentally establish a 343 344 connection between PUFAs-derived endocannabinoids and the GPR12 receptor will 345 support our findings.

It is made available under a CC-BY-NC 4.0 International license .

346

347 A significant strength of our study is the large sample with complete dietary, genomic, 348 and NMR PUFA information. We also performed our analyses at both the variant and 349 gene levels and estimated the contributions of genome-wide gene-FOS interactions to 350 the phenotypic variance of circulating PUFA traits, providing the most extensive analysis 351 of gene-FOS interactions. However, our study has several limitations. Firstly, we 352 restricted this study to European-ancestry participants and did not have large enough 353 datasets to replicate these results in other populations. Large enough datasets with the 354 necessary exposure, genomic, and phenotypic information to detect interactions are still 355 uncommon. Secondly, for FOS information, we relied on only one dietary questionnaire 356 administered to participants at one time point. This questionnaire did not give estimates 357 of the frequency of FOS intake, such as daily or weekly. It also did not provide 358 information on the types and compositions of FOS. Hence, we could not account for 359 dosage heterogeneity in our model. Thirdly, other dietary sources of omega-6 and 360 omega-3 PUFAs, such as vegetable oils and fatty fish, can alter circulating PUFA levels.^{5,6,42} Furthermore, FOS status is correlated with other lifestyle and socioeconomic 361 factors.⁴⁷ There is a possibility that the significant interactions we observed in our 362 363 results were instead driven by other exposures that we did not explore in this study. 364 However, our study had enough statistical power and was rigorous enough to replicate 365 the FADS locus, giving credibility to our findings.

366

367 Conclusion

It is made available under a CC-BY-NC 4.0 International license .

368	Our study revealed a novel locus that significantly alters the effect of FOS on PUFAs-
369	related traits. Taking genetic information into account when making nutritional
370	recommendations is the hallmark of precision nutrition, which aims to move away from a
371	one-size-fits-all dietary recommendation model. Variants that influence the effects of
372	dietary PUFAs on plasma PUFAs will help inform diet-based disease prevention and
373	treatment strategies. Additionally, accounting for gene-FOS interactions will aid in
374	developing more accurate polygenic scores for PUFAs-related traits or PUFAs-
375	associated diseases. Lastly, our study also brings to light a potentially unexplored
376	association between the GPR12 gene and PUFAs. A future research direction to
377	experimentally validate this association may highlight PUFA supplementation as a
378	potential treatment for GPR12-related diseases, such as schizophrenia.48
270	

It is made available under a CC-BY-NC 4.0 International license .

Description of Supplemental Information

381 Supplemental information includes five figures and six tables.

Declaration of Competing Interests

383 The authors declare no conflict of interest.

384 Acknowledgments

- 385 We would like to acknowledge and express gratitude to the UK Biobank participants and
- 386 administrative staff. Research reported in this publication was supported by the National
- 387 Institute of General Medical Sciences of the National Institute of Health under the award
- number R35GM143060 (KY). The content is solely the authors' responsibility and does
- 389 not necessarily represent the official views of the National Institutes of Health.

390 Data and Code Availability

- 391 Data processed in this study was made available through the UK Biobank and accessed
- 392 via an approved application. Data are not publicly available and can be accessed by
- 393 applying through <u>https://www.ukbiobank.ac.uk/enable-your-research/register</u>. Summary
- 394 statistics will be available in the GWAS Catalog (<u>https://www.ebi.ac.uk/gwas/</u>) after
- 395 publication. Scripts used to process the data, perform analysis, and interpret results are
- 396 available on GitHub (<u>https://github.com/adannasusan/PUFA-GxE</u>).
- 397

It is made available under a CC-BY-NC 4.0 International license .

398 **References**

- Lemaitre, R.N., Tanaka, T., Tang, W., Manichaikul, A., Foy, M., Kabagambe, E.K.,
 Nettleton, J.A., King, I.B., Weng, L.C., Bhattacharya, S., et al. (2011). Genetic loci
 associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome wide association studies from the CHARGE Consortium. PLoS Genet 7,
 e1002193. 10.1371/journal.pgen.1002193.
- 404
 404
 405
 405
 406
 406
 406
 406
 407
 408
 408
 408
 404
 405
 407
 408
 408
 408
 409
 409
 409
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
- Tintle, N.L., Pottala, J.V., Lacey, S., Ramachandran, V., Westra, J., Rogers, A.,
 Clark, J., Olthoff, B., Larson, M., Harris, W., and Shearer, G.C. (2015). A genomewide association study of saturated, mono- and polyunsaturated red blood cell
 fatty acids in the Framingham Heart Offspring Study. Prostaglandins Leukot
 Essent Fatty Acids *94*, 65-72. 10.1016/j.plefa.2014.11.007.
- 414
 4. Schuchardt, J.P., Ostermann, A.I., Stork, L., Kutzner, L., Kohrs, H., Greupner, T.,
 415
 416
 416
 416
 417
 417
 417
 418
 417
 418
 419
 419
 410
 410
 410
 411
 411
 411
 411
 411
 412
 412
 412
 413
 414
 415
 415
 415
 416
 417
 417
 417
 418
 419
 419
 410
 410
 410
 411
 411
 411
 412
 412
 412
 413
 414
 414
 414
 415
 414
 415
 414
 415
 415
 415
 416
 417
 417
 417
 418
 417
 418
 419
 419
 419
 410
 410
 410
 411
 411
 411
 412
 412
 412
 412
 413
 414
 414
 415
 415
 414
 415
 415
 415
 416
 417
 417
 417
 418
 418
 419
 419
 419
 410
 411
 411
 411
 412
 412
 412
 412
 412
 413
 414
 414
 415
 414
 415
 414
 415
 414
 415
 415
 415
 414
 415
 415
 415
 416
 417
 417
 418
 418
 418
 419
 419
 419
 419
 419
 410
 410
 410
 411
 411
 412
 412
 414
 414
 415
 414
 415
 414
 414
 414
 414
 414
 414
 414
 414<
- Hodge, A.M., Simpson, J.A., Gibson, R.A., Sinclair, A.J., Makrides, M., O'Dea, K.,
 English, D.R., and Giles, G.G. (2007). Plasma phospholipid fatty acid
 composition as a biomarker of habitual dietary fat intake in an ethnically diverse
 Abita Match. Combined 200, 24, 205
- 421 cohort. Nutr Metab Cardiovasc Dis *17*, 415-426. 10.1016/j.numecd.2006.04.005.
 422 6. Huybrechts, I., Jacobs, I., Aglago, E.K., Yammine, S., Matta, M., Schmidt, J.A.,
- 423 Casagrande, C., Nicolas, G., Biessy, C., Van Puyvelde, H., et al. (2023).
 424 Associations between Fatty Acid Intakes and Plasma Phospholipid Fatty Acid
 425 Concentrations in the European Prospective Investigation into Cancer and
 426 Nutrition. Nutrients *15*. 10.3390/nu15173695.
- Chilton, F.H., Murphy, R.C., Wilson, B.A., Sergeant, S., Ainsworth, H., Seeds,
 M.C., and Mathias, R.A. (2014). Diet-gene interactions and PUFA metabolism: a
 potential contributor to health disparities and human diseases. Nutrients *6*, 19932022. 10.3390/nu6051993.
- 8. Chilton, F.H., Dutta, R., Reynolds, L.M., Sergeant, S., Mathias, R.A., and Seeds,
 M.C. (2017). Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A
 Case for Personalized Supplementation Approaches for the Prevention and
 Management of Human Diseases. Nutrients *9*. 10.3390/nu9111165.
- 435
 435
 436
 436
 437
 436
 437
 436
 437
 437
 437
 438
 437
 439
 439
 439
 430
 430
 431
 431
 431
 432
 433
 434
 435
 435
 435
 437
 437
 438
 437
 438
 437
 438
 437
 438
 439
 439
 439
 430
 431
 431
 431
 432
 431
 432
 433
 433
 434
 434
 435
 435
 435
 436
 437
 437
 437
 438
 437
 438
 437
 438
 437
 438
 437
 438
 437
 438
 438
 437
 438
 438
 438
 439
 439
 439
 431
 431
 431
 432
 431
 431
 432
 431
 432
 431
 432
 432
 433
 434
 434
 435
 435
 437
 438
 438
 438
 438
 439
 439
 439
 439
 439
 439
 431
 431
 431
 432
 432
 432
 433
 434
 434
 435
 435
 434
 436
 437
 436
 437
 437
 438
 438
 438
 438
 438
 439
 439
 439
 431
 431
 431
 432
 431
 432
 431
 432
 431
 431
 432
 431
 432
 431
 432
 431
 431
 431
 431
 431
 431
 431
 431
 431
 432
 431
 431
 432
- 438 10. Saravanan, P., Davidson, N.C., Schmidt, E.B., and Calder, P.C. (2010).
 439 Cardiovascular effects of marine omega-3 fatty acids. Lancet *376*, 540-550.
 440 10.1016/S0140-6736(10)60445-X.
- Harris, W.S., Pottala, J.V., Sands, S.A., and Jones, P.G. (2007). Comparison of
 the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells

443		and plasma phospholipids. Am J Clin Nutr 86, 1621-1625.
444		10.1093/ajcn/86.5.1621.
445	12.	Juan, J., Huang, H., Jiang, X., Ardisson Korat, A.V., Song, M., Sun, Q., Willett,
446		W.C., Jensen, M.K., and Kraft, P. (2018). Joint effects of fatty acid desaturase 1
447		polymorphisms and dietary polyunsaturated fatty acid intake on circulating fatty
448		acid proportions. Am J Clin Nutr 107, 826-833. 10.1093/ajcn/nqy025.
449	13.	Sergeant, S., Hallmark, B., Mathias, R.A., Mustin, T.L., Ivester, P., Bohannon,
450		M.L., Ruczinski, I., Johnstone, L., Seeds, M.C., and Chilton, F.H. (2020).
451		Prospective clinical trial examining the impact of genetic variation in FADS1 on
452		the metabolism of linoleic acid- and □-linolenic acid-containing botanical oils. Am
453		J Clin Nutr <i>111</i> , 1068-1078. 10.1093/ajcn/nqaa023.
454	14.	Saleh, R.N.M., West, A.L., Ostermann, A.I., Schebb, N.H., Calder, P.C., and
455		Minihane, A.M. (2021). APOE Genotype Modifies the Plasma Oxylipin Response
456		to Omega-3 Polyunsaturated Fatty Acid Supplementation in Healthy Individuals.
457		Front Nutr 8, 723813. 10.3389/fnut.2021.723813.
458	15.	Tomaszewski, N., He, X., Solomon, V., Lee, M., Mack, W.J., Quinn, J.F., Braskie,
459		M.N., and Yassine, H.N. (2020). Effect of APOE Genotype on Plasma
460		Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and
461		Hippocampal Volume in the Alzheimer's Disease Cooperative Study-Sponsored
462		DHA Clinical Trial. J Alzheimers Dis 74, 975-990. 10.3233/JAD-191017.
463	16.	Yassine, H.N., Rawat, V., Mack, W.J., Quinn, J.F., Yurko-Mauro, K., Bailey-Hall,
464		E., Aisen, P.S., Chui, H.C., and Schneider, L.S. (2016). The effect of APOE
465		genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
466	47	Alzheimers Res Ther 8, 25. 10.1186/s13195-016-0194-x.
467	17.	Stephensen, C.B., Armstrong, P., Newman, J.W., Pedersen, I.L., Legault, J.,
468		Schuster, G.U., Kelley, D., Vikman, S., Hartiala, J., Nassir, R., et al. (2011).
469		ALOX5 gene variants affect elcosanoid production and response to fish oil
470	4.0	supplementation. J Lipid Res 52, 991-1003. 10.1194/JIF.P012864.
4/1	18.	Armstrong, P., Kelley, D.S., Newman, J.W., Staggers, F.E., Sr., Hartiala, J.,
472		Allayee, H., and Stephensen, C.B. (2012). Alachidonate 5-lipoxygenase gene
4/5		Variants anect response to fish oil supplementation by healthy African Americans.
4/4	10	J Null 142, 1417-1420. 10.3943/j11.112.139014.
475	19.	(2017) Conomo Wide Interaction Study of Omoreo 2 DUEAe and Other Fatty
470		(2017). Genome-Wide Interaction Study of Omega-5 POFAS and Other Fally
477		Hoart Study Nutriante 0, 10, 2200/pu0080000
470	20	Palaton I.C. Matravadia S. Gaudia N. Holloway G.P. and Mutch D.M.
479	20.	(2015) Polyupsaturated fatty acid regulation of adipocyte EADS1 and EADS2
400		(2013). Folyunsaturateu latty acturegulation of autpocyte r ADST and r ADS2 expression and function. Obesity (Silver Spring) 22, 725-728
401		10 1002/oby 21035
402 183	21	Merino D.M. Ma D.W. and Mutch D.M. (2010) Cenetic variation in linid
<u>48</u> 4	۲۱.	desaturases and its impact on the development of human disease. Linide Health
485		Dis 9 63 10 1186/1476-511X-9-63
486	22	Madden, J., Williams, C.M., Calder, P.C., Lietz, G., Miles, F.A., Cordell, H.
487		Mathers, J.C., and Minihane, A.M. (2011). The impact of common dene variants
488		on the response of biomarkers of cardiovascular disease (CVD) risk to increased

489 fish oil fatty acids intakes. Annu Rev Nutr 31, 203-234. 10.1146/annurev-nutr-490 010411-095239. 491 23. Schulze, M.B., Minihane, A.M., Saleh, R.N.M., and Riserus, U. (2020). Intake and 492 metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional 493 implications for cardiometabolic diseases. Lancet Diabetes Endocrinol 8, 915-494 930. 10.1016/S2213-8587(20)30148-0. 495 24. Huang, L., Zhang, F., Xu, P., Zhou, Y., Liu, Y., Zhang, H., Tan, X., Ge, X., Xu, Y., 496 Guo, M., and Long, Y. (2023). Effect of Omega-3 Polyunsaturated Fatty Acids on 497 Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of 498 Randomized Controlled Trials. Adv Nutr 14, 629-636. 499 10.1016/j.advnut.2023.04.009. 500 25. Wu, S., Ding, Y., Wu, F., Li, R., Hou, J., and Mao, P. (2015). Omega-3 fatty acids 501 intake and risks of dementia and Alzheimer's disease: a meta-analysis. Neurosci 502 Biobehav Rev 48, 1-9. 10.1016/j.neubiorev.2014.11.008. 503 Kavyani, Z., Musazadeh, V., Fathi, S., Hossein Faghfouri, A., Dehghan, P., and 26. 504 Sarmadi, B. (2022). Efficacy of the omega-3 fatty acids supplementation on 505 inflammatory biomarkers: An umbrella meta-analysis. Int Immunopharmacol 111, 506 109104. 10.1016/j.intimp.2022.109104. 507 27. Wei, L., Wu, Z., and Chen, Y.Q. (2022). Multi-targeted therapy of cancer by 508 omega-3 fatty acids-an update. Cancer Lett 526, 193-204. 509 10.1016/j.canlet.2021.11.023. 510 28. Francis, M., Li, C., Sun, Y., Zhou, J., Li, X., Brenna, J.T., and Ye, K. (2021). 511 Genome-wide association study of fish oil supplementation on lipid traits in 512 81,246 individuals reveals new gene-diet interaction loci. PLoS Genet 17, 513 e1009431. 10.1371/journal.pgen.1009431. 514 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, 29. 515 A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank 516 resource with deep phenotyping and genomic data. Nature 562, 203-209. 517 10.1038/s41586-018-0579-z. 518 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., 30. 519 Elliott, P., Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of 520 middle and old age. PLoS Med 12, e1001779. 10.1371/journal.pmed.1001779. 521 31. 522 Karczewski, K.J., Gupta, R., Kanai, M., Lu, W., Tsuo, K., Wang, Y., Walters, R.K., 523 Turley, P., Callier, S., Shah, N.N., et al. (2024). Pan-UK Biobank GWAS improves 524 discovery, analysis of genetic architecture, and resolution into ancestry-enriched 525 effects. medRxiv, 2024.2003.2013.24303864. 10.1101/2024.03.13.24303864. 526 32. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer 527 528 datasets. Gigascience 4. 7. 10.1186/s13742-015-0047-8. 529 33. Westerman, K.E., Pham, D.T., Hong, L., Chen, Y., Sevilla-Gonzalez, M., Sung, 530 Y.J., Sun, Y.V., Morrison, A.C., Chen, H., and Manning, A.K. (2021). GEM: 531 scalable and flexible gene-environment interaction analysis in millions of 532 samples. Bioinformatics 37, 3514-3520. 10.1093/bioinformatics/btab223.

533 34. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). 534 Functional mapping and annotation of genetic associations with FUMA. Nat 535 Commun 8, 1826. 10.1038/s41467-017-01261-5. 536 35. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: 537 generalized gene-set analysis of GWAS data. PLoS Comput Biol 11, e1004219. 538 10.1371/journal.pcbi.1004219. 539 36. Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, 540 J.M., Torstenson, E.S., Shah, K.P., Garcia, T., Edwards, T.L., et al. (2018). 541 Exploring the phenotypic consequences of tissue specific gene expression 542 variation inferred from GWAS summary statistics. Nat Commun 9, 1825. 10.1038/s41467-018-03621-1. 543 544 37. Barbeira, A.N., Pividori, M., Zheng, J., Wheeler, H.E., Nicolae, D.L., and Im, H.K. 545 (2019). Integrating predicted transcriptome from multiple tissues improves 546 association detection. PLoS Genet 15, e1007889. 547 10.1371/journal.pgen.1007889. 548 38. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders, A.K., Nyholt, D.R., 549 Madden, P.A., Heath, A.C., Martin, N.G., Montgomery, G.W., et al. (2010). 550 Common SNPs explain a large proportion of the heritability for human height. Nat 551 Genet 42, 565-569. 10.1038/ng.608. Takkunen, M.J., de Mello, V.D., Schwab, U.S., Kuusisto, J., Vaittinen, M., Agren, 552 39. 553 J.J., Laakso, M., Pihlajamaki, J., and Uusitupa, M.I. (2016). Gene-diet interaction 554 of a common FADS1 variant with marine polyunsaturated fatty acids for fatty acid 555 composition in plasma and erythrocytes among men. Mol Nutr Food Res 60, 381-389. 10.1002/mnfr.201500594. 556 557 40. Roke, K., and Mutch, D.M. (2014). The role of FADS1/2 polymorphisms on 558 cardiometabolic markers and fatty acid profiles in young adults consuming fish oil 559 supplements. Nutrients 6, 2290-2304. 10.3390/nu6062290. Al-Hilal, M., Alsaleh, A., Maniou, Z., Lewis, F.J., Hall, W.L., Sanders, T.A., O'Dell, 560 41. 561 S.D., and team, M.s. (2013). Genetic variation at the FADS1-FADS2 gene locus 562 influences delta-5 desaturase activity and LC-PUFA proportions after fish oil 563 supplement. J Lipid Res 54, 542-551. 10.1194/jlr.P032276. Ma. J., Folsom, A.R., Shahar, E., and Eckfeldt, J.H. (1995). Plasma fatty acid 564 42. 565 composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Clin 566 567 Nutr 62, 564-571. 10.1093/ajcn/62.3.564. 568 43. Blasbalg, T.L., Hibbeln, J.R., Ramsden, C.E., Majchrzak, S.F., and Rawlings, 569 R.R. (2011). Changes in consumption of omega-3 and omega-6 fatty acids in the 570 United States during the 20th century. Am J Clin Nutr 93, 950-962. 571 10.3945/ajcn.110.006643. 572 Brown, K.J., Laun, A.S., and Song, Z.H. (2017). Cannabidiol, a novel inverse 44. 573 agonist for GPR12. Biochem Biophys Res Commun 493, 451-454. 574 10.1016/i.bbrc.2017.09.001. Laun, A.S., Shrader, S.H., Brown, K.J., and Song, Z.H. (2019). GPR3, GPR6, 575 45. 576 and GPR12 as novel molecular targets: their biological functions and interaction 577 with cannabidiol. Acta Pharmacol Sin 40, 300-308. 10.1038/s41401-018-0031-9.

- 578
 46.
 Cascio, M.G. (2013). PUFA-derived endocannabinoids: an overview. Proc Nutr

 579
 Soc 72, 451-459. 10.1017/S0029665113003418.
- 580 47. Cundiff, D.K., Lanou, A.J., and Nigg, C.R. (2007). Relation of omega-3 Fatty Acid
 581 intake to other dietary factors known to reduce coronary heart disease risk. Am J
 582 Cardiol *99*, 1230-1233. 10.1016/j.amjcard.2006.12.032.
- 48. Lu, Y., Hatzipantelis, C.J., Langmead, C.J., and Stewart, G.D. (2023). Molecular
 insights into orphan G protein-coupled receptors relevant to schizophrenia. Br J
 Pharmacol. 10.1111/bph.16221.
- 586

It is made available under a CC-BY-NC 4.0 International license .

587 Figure titles and legends

Figure 1. FADS variants with significant interaction signals ($p < 5.0 \times 10^{-8}$) in five PUFA 588 589 traits. A) Circular Manhattan plots of p-values for gene-FOS interactions on omega-3. 590 omega-3%, DHA, DHA%, and the ratio of omega-6 to omega-3. B) LocusZoom plot of 591 the FADS locus for omega-3%. C) Marginal genetic effect of rs35473591 on omega-3% 592 in stratified exposure subgroups. D) Marginal exposure effects of FOS on omega-3% in 593 stratified genotype subgroups. All error bars represent 95% confidence intervals. 594 Figure 2. Significant gene-level interactions for Omega-3% and PUFAs%. Gene-level 595 Manhattan plots from MAGMA analysis for genes that reached the significance threshold of $p < 2.66 \times 10^{-6}$ in A) Omega-3% and B) PUFAs%, C) Marginal genetic 596 597 effect of rs1752653 on PUFAs% in stratified exposure subgroups. Error bars show 95% 598 confidence intervals. D) Marginal exposure effects of FOS on PUFAs% in stratified 599 genotype subgroups. Error bars represent 95% confidence intervals. **Figure 3.** *GPR12* variant with suggestive genome-wide significance ($p < 5.0 \times 10^{-6}$) in 600 601 PUFAs%, A) LocusZoom plot of the GPR12 locus for PUFAs%, B) Marginal genetic 602 effect of rs1752653 on PUFAs% in stratified exposure subgroups. C) Marginal exposure 603 effects of FOS on PUFAs% in stratified genotype subgroups. All error bars represent 604 95% confidence intervals. 605 Figure 4. The proportion of phenotypic variance explained by genome-wide gene-FOS

606 interactions in the combined dataset.

It is made available under a CC-BY-NC 4.0 International license .

607 Supplementary Figures

- 608 **Figure S1.** Participant flowchart.
- 609 **Figure S2.** Manhattan and QQ plots of p-values for gene-FOS interactions in 14 PUFAs
- and MUFAs-related phenotypes for 85,708 participants in the Phase One dataset.
- 611 **Figure S3.** Scatter plots of *p*-values, across the genome, of gene-FOS interactions
- across 14 PUFAs and MUFAs-related phenotypes in the Phases One and Two
- 613 datasets.
- **Figure S4.** Manhattan and QQ plots of p-values for gene-fish oil interactions in 14
- 615 PUFAs and MUFAs-related phenotypes for 114,352 participants in the Phase Two
- 616 dataset.
- 617 **Figure S5**. Manhattan and QQ plots of p-values for gene-fish oil interactions in 14
- 618 PUFAs and MUFAs-related phenotypes for 200,060 participants in the combined
- 619 dataset.

It is made available under a CC-BY-NC 4.0 International license .

620 Supplementary Tables

- 621 **Table S1**. Baseline characteristics of participants in Phase One, Phase Two, and
- 622 combined releases of NMR metabolite data of individuals of European ancestry in UK
- 623 Biobank
- 624 **Table S2**. GWIS summary statistics of significant and suggestive gene-FOS interactions
- in 14 PUFAs and MUFAs-related phenotypes for 85,708 participants in the Phase One
- 626 dataset
- 627 **Table S3**. GWIS summary statistics of significant and suggestive gene-FOS interactions
- in 14 PUFAs and MUFAs-related phenotypes for 114,352 participants in the Phase Two
- 629 dataset
- 630 **Table S4**. GWIS summary statistics of significant and suggestive gene-FOS interactions
- in 14 PUFAs and MUFAs-related phenotypes for 200,060 participants in the combined
- 632 dataset
- 633 **Table S5**. S-MultiXcan summary of gene-tissue associations
- **Table S6**. Estimates of SNP-based heritability and phenotypic variance explained by
- 635 gene-FOS interactions

Table 1. Lead SNPs in traits with genome-wide significant interaction signals. All significant variants are in the *FADS1*-*FADS2* gene cluster.

rsID	Chr	Pos	Nearest gene	EA	NEA	PUFA trait	Interaction	Interaction	Interaction
				(frequency)			<i>p-</i> value	Beta	S.E.
rs35473591	11	61586328	FADS1-	C (0.66)	СТ	Omega-3%	$2.50 imes 10^{-23}$	-0.0722	0.00726
			FADS2						
						Omega-6 to	1.09×10^{-20}	0.0672	0.00720
						Omega-3 ratio			
						Omega-3	2.74×10^{-17}	-0.0595	0.00704
						DHA	1.56×10^{-12}	-0.0492	0.00696
rs174535	11	61551356	MYRF	T (0.65)	С	DHA%	4.11 × 10 ⁻⁸	-0.0390	0.00718

EA, effect allele; NEA, non-effect allele; S.E., standard error

It is made available under a CC-BY-NC 4.0 International license .







А



Circulating PUFAs and MUFAs phenotype